Literature DB >> 6091067

Receptor-mediated binding and uptake of GnRH agonist and antagonist by pituitary cells.

L Jennes, W E Stumpf, P M Conn.   

Abstract

The intracellular pathway of an enzyme resistant GnRH agonist (D-Lys6-GnRH) conjugated to ferritin or to colloidal gold was followed in cultured pituitary cells. After an initial uniform distribution over the cell surface of gonadotropes, the electrondense marker was internalized, either individually or in small groups. Some, but not all marker was associated with invaginated membrane specializations showing a proteineous coat at their cytoplasmic site. After longer incubation times, the marker appeared in the lysosomal compartment and the Golgi apparatus, where it could be found in the vesicular as well as cisternal portion. In addition, the receptor-mediated endocytosis of the GnRH antagonist D-p-Glu1-D-Phe2-D-Trp3-D-Lys6-GnRH was studied by light and electron microscopic autoradiography after 30 and 60 min of incubation to ensure uptake. At both time points, in in vitro as well as in vivo studies, silver grains were localized over cytoplasmic organelles of castration cells, including dilated endoplasmic reticulum, lysosomes, and clear vesicles. No consistent association with cell nuclei, mitochondria, or secretory vesicles could be observed. The results suggest that both agonist and antagonist are binding selectively to the plasma membrane of gonadotropes and subsequently are taken up via receptor-mediated endocytosis for degradation or possible action on synthetic processes.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6091067     DOI: 10.1016/0196-9781(84)90279-1

Source DB:  PubMed          Journal:  Peptides        ISSN: 0196-9781            Impact factor:   3.750


  6 in total

1.  Target-Mediated Drug Disposition Pharmacokinetic-Pharmacodynamic Model of Bosentan and Endothelin-1.

Authors:  Anke-Katrin Volz; Andreas Krause; Walter Emil Haefeli; Jasper Dingemanse; Thorsten Lehr
Journal:  Clin Pharmacokinet       Date:  2017-12       Impact factor: 6.447

Review 2.  Trafficking and quality control of the gonadotropin releasing hormone receptor in health and disease.

Authors:  P Michael Conn; Jo Ann Janovick
Journal:  Mol Cell Endocrinol       Date:  2008-11-18       Impact factor: 4.102

3.  Evidence for an association between calmodulin and membrane patches containing gonadotropin-releasing hormone--receptor complexes in cultured gonadotropes.

Authors:  L Jennes; D Bronson; W E Stumpf; P M Conn
Journal:  Cell Tissue Res       Date:  1985       Impact factor: 5.249

4.  Analogues of luteinizing hormone-releasing hormone containing cytotoxic groups.

Authors:  T Janáky; A Juhász; S Bajusz; V Csernus; G Srkalovic; L Bokser; S Milovanovic; T W Redding; Z Rékási; A Nagy
Journal:  Proc Natl Acad Sci U S A       Date:  1992-02-01       Impact factor: 11.205

Review 5.  Therapeutic potential of β-arrestin- and G protein-biased agonists.

Authors:  Erin J Whalen; Sudarshan Rajagopal; Robert J Lefkowitz
Journal:  Trends Mol Med       Date:  2010-12-21       Impact factor: 11.951

Review 6.  Mathematical modeling of gonadotropin-releasing hormone signaling.

Authors:  Amitesh Pratap; Kathryn L Garner; Margaritis Voliotis; Krasimira Tsaneva-Atanasova; Craig A McArdle
Journal:  Mol Cell Endocrinol       Date:  2016-08-17       Impact factor: 4.102

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.